The poster presentation at the Military Health System Research Symposium investigated the use of the ABC compound in an animal study.

Portland, OR, Sept. 29, 2022 (GLOBE NEWSWIRE) -- A preclinical study presented at the Military Health System Research Symposium (MHSRS) this month demonstrated that the proprietary† Absorbable Biocompatible Chitosan (ABC) investigational product from Tricol Biomedical is both absorbable and biocompatible in an internal bleeding rodent model.

The poster presentation, Development of Bioabsorbable Chitosan Hemostatic Wound Dressing by Hua Xie and others, investigated the bioabsorption kinetics and biocompatibility of the ABC dressing when placed intraperitoneally on an injured liver lobe and subcutaneously in 16 animal subjects.

The authors describe the evaluation: “Exsanguinating hemorrhage is the leading cause of death of soldier in wartime and the second leading cause of death in civilian traumatic injuries. Quickly accessing and stabilizing the wound with effective hemostatic techniques is the key for life saving in these events. Historically, HemCon® chitosan hemostatic dressings (composed of chitosan with degree of deacetylation above 78 percent that is not readily bioabsorbable) were developed to address severe hemorrhage for external applications. In this study an absorbable, biocompatible chitosan (ABC) is prepared with a lower and narrow range of degree of deacetylation to provide a chitosan dressing material with good hemostatic properties that bioabsorbs without biodegradation induced fragmentation, and without adverse cytokine mediated inflammatory responses. The open structure, freeze dried porous matrix ABC dressing of the study is designed to facilitate biodegradation by providing enhanced cellular infiltration and proliferation.”

The results of the preclinical study demonstrated:

Desirable bioabsorption properties and biocompatibility of the ABC dressing in both subcutaneous and intraperitoneal implantation models.

The ABC dressing implant was 85% absorbed in 28 days and close to fully absorbed within 60 to 90 days at both implantation sites.

The ABC chitosan dressing demonstrates absorbable biocompatibility without systemic or local adverse responses.

The ABC chitosan dressing does not result in surgical adhesion formation greater than Grade 2 – no surgical adhesions were observed.

“The proof of principle within this preclinical study demonstrates a significant potential to address internal bleeding with our mucoadhesive controlled dissolution product line,” commented Christopher Rowland, Tricol’s President and CEO.  “Tricol has a long history of innovation and is committed to further progressing technologies that cut across hospital call points, procedures, and specialties to significantly benefit the health of patients around the world.”

For more than 20 years, Tricol has been a world leader in advanced acute wound care innovation and is dedicated to expanding technologies, platforms, and applications to improve and save lives around the globe. Through strong scientific background, a highly skilled team and significant emphasis on research and development, Tricol has established itself as a global medical products company that continues to innovate its initial foundation of advanced hemostatic solutions. The company holds over 60 patents and 32 clinical publications, manufacturing life-saving Chito+™ hemostatic product families like HemCon® and OneStop®.

Tricol Biomedical, a privately held medical device company dedicated to saving lives through innovative hemostatic and wound care solutions, is fully committed to life-saving innovation in bleeding control and wound care technology. Tricol Biomedical's proprietary Chito+ products, such as the HemConTM and OneStopTM product lines, are designed to meet a variety of medical needs. These devices are used to stop bleeding from trauma and in a wide variety of medical procedures requiring bleeding management. The original HemCon Bandage was designed in partnership with the U.S. Army to save the lives of soldiers who suffered traumatic injuries on the battlefield. In 2016, Tricol acquired the full HemCon product line, which can be found today in hospitals, outpatient settings, emergency clinics, and by consumers at home, work, or school.

† Protected by US 9547011; US 9846163; US9925310; US 10709817; CZ 3003026; DE 602014050166.4; CN105142399

TRICOL BIOMEDICAL'S ABC-CHITOSAN WOUND DRESSING IS AN INVESTIGATIONAL DEVICE THAT HAS NOT BEEN CLEARED BY FDA FOR INTERNAL USE.

Tests from Grail and others aim to help clinicians diagnose more cancers earlier, though data are limited.

Kiromic BioPharma Inc (NASDAQ: KRBP) received validating written feedback from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel development strategy. Deltacel is the company's most advanced therapeutic candidate, applying in allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cells (GDT). The Pre-IND meeting request was to align with and obtain FDA guidance on Kiromic's proposed development strategy about the chemistry, manufacturing, and controls (CMC)

In the latest trading session, Chesapeake Energy (CHK) closed at $101.65, marking a -0.77% move from the previous day.

Barrington Research analyst James C.Goss reiterated an Outperform rating on the shares of IMAX Corp (NYSE: IMAX) with a price target of $20. As theatres have reopened and feature film releases have become more numerous, IMAX U.S. box office has generally performed closer to its 2019 benchmark than the broader domestic industry, noted the analyst. The blockbuster-heavy slate, consumer preference for a premium experience, and typical one or two-week runs on IMAX screens play into the performance.

Schlumberger saw its IBD SmartSelect Composite Rating rise to 96 Friday, up from 94 the day before. The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. Schlumberger is not currently near a proper entry, as it is still building the right side of a cup pattern.

The major stock market indexes were down for a second day in a row. A mobile storage unit stock and energy stock broke out of bases, triggering buy points on their charts.

Bangladesh suffered its worst blackout since 2014 on Tuesday (Oct. 4), a symptom of disrupted fuel supplies and a preview of what other countries might face in the coming months.

Talks between Elon Musk and Twitter Inc. to reach a resolution of the $44 billion takeover are stuck in part over Musk's statement that his offer is now contingent on receiving $13 billion in debt financing, according to people familiar with the matter. More from BI's Mandeep Singh and Matthew Schettenhelm and Bloomberg's Ed Ludlow.

Here is how Jakks Pacific (JAKK) and PowerSchool Holdings (PWSC) have performed compared to their sector so far this year.

WASHINGTON (Reuters) -U.S. stocks tumbled on Friday after a stronger-than-expected jobs report locked in expectations that the Federal Reserve is sticking with a steady diet of rate hikes, while supply cuts continued to boost oil prices. The Dow Jones Industrial Average closed down more than 600 points, sliding 2.11%, while the S&P 500 fell 2.8% and the Nasdaq Composite lopped off 3.8% in value as investors bet that the Fed's inflation fight will continue apace. The U.S. Labor Department reported that nonfarm payrolls increased by 263,000 in September - slightly above expectations - with the jobless rate dipping to 3.5%, below forecasts.

Wall Street closed slightly lower on Wednesday, ending a two-day rally.

Acuity Brands' (AYI) fiscal fourth-quarter results benefit from higher segmental sales and price increases amid industry woes.

After around a decade of near constant growth, the stock market has been falling in recent months and we are officially in a bear market for the first time in quite a while. For younger people this is scary, but … Continue reading → The post Your Target-Date Fund May Not Be Prepared For a Down Market appeared first on SmartAsset Blog.

ENPH could bounce off a historically bullish trendline

The Reserve Bank of India will soon commence limited pilot launches of a central bank backed digital rupee for specific use cases, it said in a concept paper released on Friday. The RBI has been exploring the pros and cons of a central bank digital currency for some time and is working towards a strategy to implement it in a phased manner, it said. In February, the Indian government had said that a digital rupee will be launched during the course of this financial year.

As crypto markets turn turbulent, asset managers perform due diligence by looking at fundamentals like network usership to increase safety.

California-based Rivian is recalling about 13,000 vehicles after it discovered that a fastener connecting the front upper control arm and steering knuckle may not have been "sufficiently torqued" in some vehicles, a company spokesperson said in a statement. Electric vehicle maker has so far produced a total of 14,317 vehicles this year. Rivian notified the affected customers about the recall after it became aware of seven reports potentially related to the structural issue of torqued fastener, the company said.

These are the marijuana stocks on the Nasdaq with the best value, fastest growth, and best performance for October 2022.

(Bloomberg) -- Technology stocks are facing more pain after chipmaker Advanced Micro Devices Inc. revived fears about the upcoming earnings season after warning that third-quarter sales were softer than expected.AMD blamed disappointing preliminary results on weakness in the personal computer market, sending its shares and those of other companies involved in the sector lower in postmarket trading. AMD, Nvidia Corp., Intel Corp. and Microchip Technology Inc. were among chipmakers down more than

MARKET PULSE The judge in a legal battle between Twitter Inc. (TWTR) and Tesla Inc. (TSLA) Chief Executive Elon Musk on Thursday delayed their trial, previously set for Oct. 17, to give the sides time to close the $44 billion acquisition at the heart of the beef.